A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB plus ANASTROZOLE COMPARED TO LAPATINIB plus LETROZOLE, LETROZOLE MONOTHERAPY OR ANASTROZOLE MONOTHERAPY IN THE TREATMENT OF HER2+/HORMONE RECEPTOR POSITIVE (HR plus ) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)

被引：0
|
作者：
McNamara, S. [1 ]
Moore, L. [1 ]
Ray, J. [2 ]
机构：
[1] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[2] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A269 / A269
页数：1
相关论文
共 50 条
  • [41] BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK
    Moller, A. H.
    Oddershede, L.
    VALUE IN HEALTH, 2019, 22 : S483 - S483
  • [42] A cost-effectiveness analysis of palbociclib plus letrozole as first-line treatment for estrogen receptor-positive, HER2-negative, metastatic breast cancer.
    Matter-Walstra, Klazien
    Schwenkglenks, Matthias
    Brauchli, Peter
    Klingbiel, Dirk
    Dedes, Konstantin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Cost-utility analysis of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer (EBC): a UK National Health Service (NHS) perspective. The ATAC Trialists' Group
    Mansel, Robert E.
    ANNALS OF ONCOLOGY, 2004, 15 : 65 - 65
  • [44] MONARCH 3: A randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC).
    Goetz, Matthew P.
    Toi, Masakazu
    Klise, Suzanne
    Frenzel, Martin
    Bourayou, Nawel
    Di Leo, Angelo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
    Bao, Yuwen
    Zhang, Zhuolin
    He, Xuan
    Cai, Lele
    Wang, Xiao
    Li, Xin
    CURRENT ONCOLOGY, 2022, 29 (09) : 6053 - 6067
  • [46] General Characteristics, Patterns of Relapse and Treatment Outcomes of Patients with HER2 Amplified Metastatic Breast Cancer (MBC) who are Hormone Receptor Positive (HR plus ) Versus Hormone Receptor Negative (HR-)
    Dumbrava, Monica I.
    De Boer, Richard
    Lok, Sheau
    Gibbs, Peter
    Greenberg, Sally
    Pellegrini, Laura
    Yip, Desmond
    Malik, Laeeq
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 119 - 120
  • [47] COST-UTILITY ANALYSIS OF DABRAFENIB/TRAMETINIB COMBINATION (D plus T) FOR BRAFV600 MUTATION-POSITIVE METASTATIC MELANOMA (MM) FROM THE UNITED KINGDOM (UK) NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE
    Delea, T. E.
    Amdahl, J.
    Wang, A.
    Amonkar, M.
    Smith, H. W.
    Balaratnam, S.
    Stapelkamp, C.
    VALUE IN HEALTH, 2014, 17 (03) : A88 - A88
  • [48] Preliminary results from TRASTYVERE study: A retrospective analysis of HER2-positive (HER2) metastatic breast cancer (MBC) patients treated in Spain with lapatinib (L) plus trastuzumab (T).
    Gavila, Joaquin
    Bermejo, Begona
    Manso, Luis
    Munoz, Eva
    Anton, Antonio
    Brunet, Joan
    Rodriguez-Lescure, Alvaro
    Augusto Rodriguez, Cesar
    Santaballa, Ana
    Sanchez-Rovira, Pedro
    de la Haba-Rodriguez, Juan
    Santisteban, Marta
    Ruiz Borrego, Manuel
    Cortes, Javier
    Llombart-Cussac, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER FROM A US PRIVATE THIRD-PARTY PAYER PERSPECTIVE
    Mistry, R.
    Suri, G.
    Young, K. C.
    Hettle, R.
    May, J. R.
    Brixner, D.
    Oderda, G.
    Biskupiak, J.
    Tang, D.
    Bhattacharyya, D.
    Bhattacharyya, S.
    Mishra, D.
    Dalal, A.
    VALUE IN HEALTH, 2017, 20 (09) : A422 - A423
  • [50] Ribociclib plus letrozole for first-line treatment of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers
    Andre, Fabrice
    Stemmer, Salomon M.
    Campone, Mario
    Petrakova, Katarina
    Paluch-Shimon, Shani
    Yap, Yoon-Sim
    Marschner, Norbert
    Chan, Arlene
    Villanueva, Cristian
    Hart, Lowell L.
    Arteaga, Carlos L.
    Sonke, Gabe S.
    Grischke, Eva-Maria
    Alba, Emilio
    Nusch, Arnd
    Yardley, Denise A.
    Jakobsen, Erik
    Blau, Sibel
    Tolaney, Sara M.
    Su, Faye
    He, Wei
    Germa, Caroline
    Hortobagyi, Gabriel N.
    CANCER RESEARCH, 2017, 77
12345